Similar articles

• Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel: a commentary.

  Madkour N, Bounthavong M. Madkour N, et al. Pharmacotherapy. 2012 Jun;32(6):e170; discussion e170-1. doi: 10.1002/j.1875-9114.2012.01143_1.x. Pharmacotherapy. 2012. PMID: 22674743 No abstract available.
• Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.

  Reese ES, Daniel Mullins C, Beitelshees AL, Onukwugha E. Reese ES, et al. Pharmacotherapy. 2012 Apr;32(4):323-32. doi: 10.1002/j.1875-9114.2012.01048. Pharmacotherapy. 2012. PMID: 22461122 Free PMC article.
• The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.

  Panattoni L, Brown PM, Te Ao B, Webster M, Gladding P. Panattoni L, et al. Pharmacoeconomics. 2012 Nov 1;30(11):1067-84. doi: 10.2165/11595080-000000000-00000. Pharmacoeconomics. 2012. PMID: 22974536
• Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient).

  Wynn RL. Wynn RL. Gen Dent. 2010 Jan-Feb;58(1):7-9. Gen Dent. 2010. PMID: 20129886 Review. No abstract available.
• Prasugrel (Effient) vs. clopidogrel (Plavix).

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2009 Sep 7;51(1320):69-70. Med Lett Drugs Ther. 2009. PMID: 19738549 Review.